Advertisement
U.S. markets closed
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,140.00
    -36.00 (-0.09%)
     
  • Nasdaq Futures

    18,465.00
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,145.20
    +6.80 (+0.32%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0786
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • Vix

    13.01
    +0.23 (+1.80%)
     
  • GBP/USD

    1.2629
    +0.0007 (+0.05%)
     
  • USD/JPY

    151.3390
    -0.0330 (-0.02%)
     
  • Bitcoin USD

    70,825.89
    +1,306.45 (+1.88%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,342.31
    +174.24 (+0.43%)
     

Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences

NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V

OrganiGram Holdings Inc.
https://rdinvesting.com/news/?ticker=OGI.V

Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO

Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO

Emblem's stock edged 0.83% lower Thursday, to close the day at $1.20. The stock recorded a trading volume of 441,760 shares, which was above its three months average volume of 298,366 shares. In the last year, Emblem's shares have traded in a range of 1.09 - 2.76. The stock is currently trading 56.52% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.26 is below its 200-day moving average of $1.47.Shares of Emblem have fallen approximately 47.37 percent year-to-date.

Access RDI's Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V

On Thursday, shares of OrganiGram Holdings recorded a trading volume of 176,251 shares, which was below the three months average volume of 754,957 shares. The stock ended the day 0.77% lower at 5.18. The share price has gained 145.50% from its 52 week low with a 52 week trading range of 2.11 - 5.93. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.02 is greater than its 200-day moving average of $4.59. Shares of OrganiGram Holdings have gained approximately 26.34 percent year-to-date.

Access RDI's OrganiGram Holdings Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OGI.V

Oncolytics Biotech's stock moved 2.73% higher Thursday, to close the day at $5.64. The stock recorded a trading volume of 13,521 shares, which was below its three months average volume of 32,395 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 4.57 - 10.67. The share price has gained 23.41% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $6.90 is below its 200-day moving average of $7.19. Shares of Oncolytics Biotech have fallen approximately 16.59 percent year-to-date.

Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO

On Thursday, shares of Aptose Biosciences recorded a trading volume of 57,635 shares, which was above the three months average volume of 40,714 shares. The stock ended the day 10.56% higher at 3.98. The share price has gained 142.68% from its 52 week low with a 52 week trading range of 1.64 - 5.97. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.42 is greater than its 200-day moving average of $4.28. Shares of Aptose Biosciences have gained approximately 43.17 percent year-to-date.

Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO

Our Actionable Research on Emblem Corp. (TSXV:EMC.V) and OrganiGram Holdings Inc. (TSXV:OGI.V) and Oncolytics Biotech Inc. (TSX:ONC.TO) and Aptose Biosciences Inc. (TSX:APS.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


Advertisement